Slide 1: Q1 2026 Financial Results
Q1 2026 Financial Results Conference call | May 7, 2026 www.materialise.com | NASDAQ & EURONEXT: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections,
Slide 3: Agenda
Agenda • Q1 2026 Business Highlights Brigitte de Vet-Veithen • Q1 2026 Financial Highlights CEO • Q1 2026 Financial Results • 2026 Financial Guidance • Q&A Koen Berges CFO 3
Slide 4: Business Update: RapidFit and Eyewear transfer
Q1 2026 Business Update Materialise transfers RapidFit and Eyewear Business to their respective management teams • Allowing us to further concentrate capital and resources on our core activities • RapidFit and Eyewear continue to operate as independent companies. • Materialise retains minority stake
Slide 5: Business Update: Medtech and Software
Q1 2026 Business Update Medtech – Making the Exceptional Accessible • CMF-portfolio expanded with custom-made PEEK implants • Launch of OrthoView 3D Hip for complex hip surgery Software – Growing Our Software Ecosystem • First customers onboard CO-AM Pro Platform offering • Magics Print for HP inclu
Slide 6: Q1 2026 Financial Highlights
Q1 2026 – Financial Highlights • Revenue of 66.3 mEUR, stable compared to Q1 2025 • Gross Profit of 37.9 mEUR, representing 57.2% of revenue • Adjusted EBIT of 2.5 mEUR, representing 3.7% of revenue • Net profit of 1.8 mEUR, representing 3 EUR-ct. per share • Net Cash position of 72.8 mEUR, represen
Slide 7: Consolidated Revenue
Q1 2026 Consolidated Revenue Q1 2026 Revenue by Segment -0.2% 66,379 66,276 Software 15% Medical 35% Manufacturing 50% Q1 2025 Q1 2026 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Revenue of 66.3 mEUR, stable compared to Q1 2025 • Unfavorable foreign exchange movement
Slide 8: Consolidated Adjusted EBIT & EBITDA
Q1 2026 Consolidated Adjusted EBIT & EBITDA 2,470 +30.9% 8,049 +282.4% 6,147 12.1% 9.3% 3.7% 646 1.0% Q1 2025 Adj. EBIT Q1 2026 Q1 2025 Adj. EBITDA Q1 2026 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2026 Adjusted EBIT increased significantly to 2.5 mEUR compared
Slide 9: Medical Segment
Q1 2026 Medical Segment +6.7% +2.1% 33,165 9,047 9,235 31,078 29.1% 27.8% Q1 2025 Revenue Q1 2026 Q1 2025 Adj. EBITDA Q1 2026 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2026 revenue increased 7% to 33.2 mEUR • Revenue from medical devices & services increased 11%
Slide 10: Software Segment
Q1 2026 Software Segment -1.4% 9,775 9,641 1,123 +87.5% 11.6% 599 6.1% Q1 2025 Revenue Q1 2026 Q1 2025 Adj. EBITDA Q1 2026 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q1 2026 revenue decreased slightly to 9.6 mEUR compared to Q1 2025 impacted by unfavorable foreign e
Slide 11: Manufacturing Segment
Q1 2026 Manufacturing Segment -8.1% 25,526 281 23,470 1.2% (1.5)% Q1 2025 Revenue Q1 2026 -377 Adj. EBITDA [Data in kEUR unless notes otherwise. All numbers and percentages rounded] Q1 2025 Q1 2026 • Q1 2026 revenue decreased by 8% to 23.5 mEUR compared to Q1 2025 but increased compared to prior 3 q
Slide 12: Income Statement Highlights
Income Statement Highlights Q1 2026 Q1 2025 Gross profit margin (in %) Revenue 66,276 66,379 57.2% Cost of sales (28,383) (29,654) Gross profit 37,894 36,724 55.3% Research & development expenses (11,890) (11,414) Sales & marketing expenses (15,435) (15,071) Q1 2025 Q1 2026 General & administrative
Slide 13: Other Financial Highlights
Other Financial Highlights Balance Sheet items 31/03/26 31/12/25 Cash flow from operations 9,713 Cash and equivalents 132,952 133,918 6,914 Borrowings 60,126 63,113 Net Cash 72,826 70,805 Q1 2025 Q1 2026 Trade receivables 55,462 54,938 Inventories 16,753 14,904 Capital expenditures (cash impact) Tra
Slide 14: 2026 Financial Guidance
2026 Financial Guidance We are maintaining our prior guidance for revenue and Adjusted EBIT despite the announced divestments of our RapidFit and Eyewear businesses. • Expect 2026 consolidated revenue within 273 - 283 mEUR range • Expect 2026 consolidated Adjusted EBIT within 10 - 12 mEUR range 14
Slide 15: Adjusted EBIT/EBITDA Reconciliation
Appendix Adjusted EBIT/EBITDA Reconciliation [Data in kEUR unless noted otherwise. All numbers and percentages rounded] Q1 2026 Q1 2025 Net profit/(loss) 1,820 (535) Income taxes 662 234 Financial expenses 700 2,772 Financial income (1,092) (1,897) EBIT 2,090 574 Depreciation & amortization 5,578 5,
Slide 16: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 16